PL2099780T3 - Związki 2-alkiloindazolu do leczenia określonych zaburzeń związanych z ośrodkowym układem nerwowym - Google Patents

Związki 2-alkiloindazolu do leczenia określonych zaburzeń związanych z ośrodkowym układem nerwowym

Info

Publication number
PL2099780T3
PL2099780T3 PL07846673T PL07846673T PL2099780T3 PL 2099780 T3 PL2099780 T3 PL 2099780T3 PL 07846673 T PL07846673 T PL 07846673T PL 07846673 T PL07846673 T PL 07846673T PL 2099780 T3 PL2099780 T3 PL 2099780T3
Authority
PL
Poland
Prior art keywords
alkyl
treatment
related disorders
indazole compounds
certain cns
Prior art date
Application number
PL07846673T
Other languages
English (en)
Inventor
Maria Alessandra Alisi
Nicola Cazzolla
Guido Furlotti
Caterina Maugeri
Rosella Ombrato
Lorenzo Polenzani
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of PL2099780T3 publication Critical patent/PL2099780T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PL07846673T 2006-11-22 2007-11-19 Związki 2-alkiloindazolu do leczenia określonych zaburzeń związanych z ośrodkowym układem nerwowym PL2099780T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002230A ITMI20062230A1 (it) 2006-11-22 2006-11-22 Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
EP07846673A EP2099780B1 (en) 2006-11-22 2007-11-19 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
PCT/EP2007/010000 WO2008061688A1 (en) 2006-11-22 2007-11-19 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders

Publications (1)

Publication Number Publication Date
PL2099780T3 true PL2099780T3 (pl) 2013-05-31

Family

ID=38474157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07846673T PL2099780T3 (pl) 2006-11-22 2007-11-19 Związki 2-alkiloindazolu do leczenia określonych zaburzeń związanych z ośrodkowym układem nerwowym

Country Status (23)

Country Link
US (1) US8507528B2 (pl)
EP (1) EP2099780B1 (pl)
JP (1) JP5551443B2 (pl)
KR (1) KR101471987B1 (pl)
CN (1) CN101558057B (pl)
AR (1) AR063881A1 (pl)
AU (1) AU2007323368B2 (pl)
BR (1) BRPI0718976A2 (pl)
CA (1) CA2668205C (pl)
DK (1) DK2099780T3 (pl)
EA (1) EA019217B1 (pl)
ES (1) ES2401199T3 (pl)
GE (1) GEP20125414B (pl)
HK (1) HK1129112A1 (pl)
IL (1) IL198432A (pl)
IT (1) ITMI20062230A1 (pl)
MX (1) MX2009005250A (pl)
PL (1) PL2099780T3 (pl)
PT (1) PT2099780E (pl)
SG (1) SG176504A1 (pl)
SI (1) SI2099780T1 (pl)
UA (1) UA98311C2 (pl)
WO (1) WO2008061688A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2788762C (en) * 2010-04-08 2018-04-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.S.P.A. Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
MX350121B (es) 2011-03-18 2017-08-28 Bayer Ip Gmbh Derivados de n-(3-carbamoilfenil)-1h-pirazol-5-carboxamida y el uso de los mismos para el control de plagas de animales.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000824A1 (en) * 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
GB8623142D0 (en) 1986-09-26 1986-10-29 Beecham Group Plc Compounds
DE3650772T2 (de) * 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
JPH02215779A (ja) * 1989-02-14 1990-08-28 Kuraray Co Ltd カルボン酸アミド誘導体類及びその医薬用途
US5246947A (en) * 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
WO1994005642A1 (en) 1992-08-28 1994-03-17 Ciba-Geigy Ag Indazole derivatives
JPH08277287A (ja) * 1995-02-09 1996-10-22 Mitsubishi Chem Corp インダゾール類およびその用途
CA2222532A1 (en) * 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Indazole derivatives having monocyclic amine
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6218390B1 (en) * 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
CA2507074A1 (en) 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
ITMI20031468A1 (it) 2003-07-18 2005-01-19 Acraf Farmaco ativo nel dolore neuropatico
FR2857966A1 (fr) * 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
EP1701951B1 (en) * 2003-12-23 2010-02-10 Serodus AS Modulators of peripheral 5-ht receptors
RU2397168C2 (ru) * 2004-01-05 2010-08-20 Астразенека Аб Производные тиофена в качестве ингибиторов снк 1
AR050279A1 (es) * 2004-08-03 2006-10-11 Wyeth Corp Indazoles como moduladores de lxr utiles en la preparacion de medicamentos pata el tratamiento de enfermedades cardiovasculares y mediadas por th1 y composiciones farmaceuticas que los contienen como principio activo.
TW200621237A (en) * 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2008054748A2 (en) * 2006-10-31 2008-05-08 Arena Pharmaceuticals, Inc. Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto

Also Published As

Publication number Publication date
BRPI0718976A2 (pt) 2014-02-04
CN101558057A (zh) 2009-10-14
CA2668205A1 (en) 2008-05-29
EP2099780A1 (en) 2009-09-16
US8507528B2 (en) 2013-08-13
WO2008061688A1 (en) 2008-05-29
HK1129112A1 (en) 2009-11-20
JP2010510265A (ja) 2010-04-02
CN101558057B (zh) 2013-05-01
EA200970496A1 (ru) 2009-10-30
EP2099780B1 (en) 2013-01-09
GEP20125414B (en) 2012-03-12
KR101471987B1 (ko) 2014-12-12
SI2099780T1 (sl) 2013-03-29
PT2099780E (pt) 2013-03-11
ES2401199T3 (es) 2013-04-17
US20100056573A1 (en) 2010-03-04
CA2668205C (en) 2014-10-21
DK2099780T3 (da) 2013-04-15
ITMI20062230A1 (it) 2008-05-23
SG176504A1 (en) 2011-12-29
AU2007323368A1 (en) 2008-05-29
IL198432A (en) 2013-03-24
JP5551443B2 (ja) 2014-07-16
IL198432A0 (en) 2010-02-17
MX2009005250A (es) 2009-05-28
UA98311C2 (ru) 2012-05-10
EA019217B1 (ru) 2014-02-28
AR063881A1 (es) 2009-02-25
KR20090089880A (ko) 2009-08-24
AU2007323368B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
IL192692A0 (en) Compounds for the treatment of inflammatory disorders
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
IL192691A0 (en) Hydantoin compounds for the treatment of inflammatory disorders
ZA200808963B (en) Compounds for the treatment of metabolic disorders
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
EP2019683A4 (en) DELIVERY OF GROWTH FACTORS TO TREAT CNS DISORDERS
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
ZA200805645B (en) Compounds for the treatment of metabolic disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
IL192851A0 (en) Compounds for the treatment of metabolic disorders
ZA200908724B (en) Spiro compounds for treatment of inflammatory disorders
ZA201204391B (en) Compounds for the treatment of neurologic disorders
IL195392A0 (en) Compounds for the treatment of metabolic disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
HK1129112A1 (en) 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
IL192982A0 (en) Compounds for the treatment of metabolic disorders
GB0604772D0 (en) Use of substituted amine compounds for the treatment of food related disorders
GB0604783D0 (en) Use of substituted oxime compounds for the treatment of food related disorders
GB0724947D0 (en) Composition for the treatment of psychiatric disorders